Hyperion Therapeutics to Present at Upcoming Investor Conferences in November
SOUTH SAN FRANCISCO, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at two investor conferences in November:
| Lazard Capital Markets 9th Annual Healthcare Conference in New York |
| Wednesday, November 14 at 2:30 p.m. ET. |
| Piper Jaffray 24th Annual Healthcare Conference in New York |
| Tuesday, November 27 at 12:30 p.m. ET. |
Donald J. Santel, Chief Executive Officer of Hyperion, will provide a company overview. To access the live webcasts and subsequent archived recordings, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm.
About Hyperion Therapeutics
Hyperion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Hyperion Therapeutics is developing Ravicti™ (glycerol phenylbutyrate) for two orphan indications: urea cycle disorders and hepatic encephalopathy.
Shari Annes, Investor Relations Cell: 650-888-0902
Hyperion Therapeutics, Inc.
Subscribe via RSS
South San Francisco, California, UNITED STATES
Symbol: HPTX
-0.84
Day's Range: 20.54-21.55
Open: 21.00
Previous Close: 21.64
TSO: 20,042,000
Market Cap: 416.87M
Day's Volume: 86,516